Extract
We read with interest the recent publication by Morice et al. [1] “The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study” and the accompanying editorial by Turner and Birring [2] “Chronic cough: ATP, afferent pathways and hypersensitivity”. The authors of both publications conclude the results are suggestive of two separate neuronal pathways mediating the cough reflex; however, there are significant issues with this interpretation of the data.
Abstract
Over interpretation of cough challenge data only adds to the confusion in our understanding of the mechanisms underlying chronic cough http://bit.ly/2X52CQt
Footnotes
Conflict of interest: J.A. Smith reports grants for commercial research and personal fees for advisory board work and consultancy from GlaxoSmithKline and Merck, grants for commercial research and personal fees for consultancy from NeRRe Pharmaceuticals, Menlo, Bayer and Axalbion, personal fees for consultancy from Boehringer Ingelheim, Genentech, Neomed, Chiesi and Bellus, non-financial support (equipment provision) from Vitalograph, grants from Afferent, research grants and personal fees for consultancy from AstraZeneca, outside the submitted work; and has a patent regarding a method for generating output data licensed.
Conflict of interest: M.A. Wortley has nothing to disclose.
Conflict of interest: S. Bonvini has nothing to disclose.
Conflict of interest: M. Birrell is an employee of AstraZeneca.
Conflict of interest: M.G. Belvisi is an employee of AstraZeneca.
- Received August 6, 2019.
- Accepted November 1, 2019.
- Copyright ©ERS 2020
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org